Although the anti-platelet therapy is a standard for a patient with acute coronary syndrome with or without coronary intervention, oral anticoagulant has not been used for long time. Several trials demonstrated the beneficial effects on the prevention of reinfarction or stroke, but the risk of serious bleeding increased. Furthermore, good adherence and control of oral anticoagulant were necessary to improve the clinical outcome. So, oral anticoagulant has not been used for the patients with acute coronary syndrome; however, direct thrombin inhibitor or direct anti-Xa have been proven to be equivalent or even better to warfarin in stroke prevention for patients with atrial fibrillation (AF). These new oral anticoagulant (NOAC) has been tested in patients with acute coronary syndrome, and showed the normal dose of NOAC for stroke prevention with dual antiplatelet increased the bleeding risk, but reduced dose of NOAC might be beneficial for the secondary prevention. This combination of anticoagulant and DAPT is especially interested, because of the anti-thrombotic regimen for patients with AF and coronary heart disease who are treated by stent. Triple therapy (warfarin and DAPT) increased bleeding complication and major cardiovascular events compared to dual therapy (warfarin and single anti-platelet) in stable coronary artery disease; however, no trials in acute coronary syndrome are available right now. Furthermore, no data are available in NOAC. Until then, the appropriate combination of NOAC and anti-platelet would be chosen by the physician who assessed the risk of bleeding and thrombosis for each patient.
I. Introduction
Coronary plaque rupture following thrombus formation is a cause of acute coronary syndrome, which is a major determinant of patients with ischemic heart disease. In late 1980, the combination of thrombolytic agent and antiplatelet proved to decrease the short-term mortality in patients with ST-segment elevation myocardial infarction (STEMI), 1) and routinely performed and became popular. This strategy was applied to the patients with non STEMI or unstable angina (UA), but failed to approve the beneficial effect on the clinical outcome. In TIMI IIIB trial,
2)
thrombolytic agent is not beneficial and may be harmful in patients with non Q-wave myocardial infarction (NQMI) and UA.
This result implicated that the underlying thrombosis mechanism in STEMI is different from that in NSTEMI and UA. Coronary angioscopic finding revealed that the red or mixed thrombus and white thrombus were observed at the culprit lesion in STEMI and NSTEMI/UA, respectively.
3) After the failed thrombolytic agent era, anti-platelet agents were tested for the patients with NSTEMI/UA. In the late 1990, several glycoprotein (GP) IIb/
IIIa antagonist were developed and tested in patients with UA and NSTEMI. GP IIb/IIIa receptor blocker abciximab did not improve the outcome in GUSTO IV-ACS, 4) but in nearly all studies involving the small-molecule GP IIb/IIIa inhibitors (eptifibatide 5) and tirofiban 6) ), the rates of death and MI were reduced in the treatment groups compared with the comparator group ; however, the difference was not always statistically significant. In all of the trials, the risk of bleeding was greater in the groups receiving a GP IIb/IIIa inhibitor than in the comparator group, but the difference was not always statistically significant. 7) These trials suggested the antiplatelet might be the key drug to prevent the myocardial infarction in patients with UA.
Another anti-platelet inhibitor, P2Y12 receptor blocker clopidogrel is a next candidate for preventing myocardial infarction.
Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) trial 8) randomized 12,562 patients with UA/NSTEMI to either dual antiplatelet therapy with aspirin plus clopidogrel or to aspirin alone immediately upon presentation. At a mean follow-up of 9 months, dual antiplatelet therapy was associated with a significant reduction in the composite primary endpoint of cardiovascular mortality, nonfatal MI, or stroke, largely due to fewer myocardial infarction. As clopidogrel has been proved to prevent cerebro cardio vascular event significantly than aspirin,
showed that warfarin, in combination with aspirin or given alone, was superior to aspirin alone in the incidence of composite endpoint, death, non fetal myocardial infarction or thrombotic cerebral stroke, but with the increase risk of bleeding. A meta-analysis of the use of warfarin in patients with acute coronary syndrome demonstrated that the warfarin or warfarin plus aspirin were superior to aspirin alone in terms of the prevention of reinfarction, but increased the incidence of major bleeding. 16) In addition, the discontinuation of oral anticoagulant as well as oral anticoagulant plus aspirin was significantly higher compared to aspirin alone in ASPECT II trial 17) and only patients who were compliant with oral anticoagulant over 70% of the time derive benefit from its administration.
18)
These results suggested that oral anticoagulant is useful for the secondary prevention in patients with acute coronary syndrome, but the retention of oral anticoagulant to the patients and keeping the good control are difficult in the real world. Aspirin alone or dual antiplatelet is widely used and become a standard care.
III. New era of oral anticoagulant
Nobel oral anticoagulant became available in 2009. First of all, dabigatran showed the superiority or non-inferiority to VKA (Vitamin K antagonist) in terms of the prevention of stroke or systemic thrombo-embolism in patients with atrial fibrillation.
19)
Three kinds of anti-Xa antagonist has become available and showed the similar effects to dabigatran in clinical trials. A meta-analysis showed that NOAC had a favorable risk-benefit profile, with significant reductions in stroke, intracranial hemorrhage, and mortality, and with similar major bleeding as for warfarin, but increased gastrointestinal bleeding. 20) In these major clinical trials, prothrombin time-international normalized ratio (PT-INR) was achieved range of 2.0-3.0 with warfarin. The evalutation of warfarin control is assessed by time in therapeutic range (TTR). TTR should be achieved over 70% to obtain the maximum protection against thromboembolism in AF.
21) It will be difficult to achieve over 70% of TTR in practice, over 60 % of TTR might be enough to prevent ischemic stroke. Four major clinical trials showed the racial difference in the onset of stroke or systemic thromboembolism and the intracranial hemorrhage under the warfarin control using PT-INR of range 2.0-3.0. There is a negative correlation between center TTR and the incidence of stroke/systemic thromboembolism both in Asians and non-Asians ; however the slope in non-Asians is steeper than that in Asians and the incidence of stroke/systemic thromboembolism is much higher in Asians compared to the non-Asians with ischemic heart disease.
In addition to the anti-platelet agent, coronary intervention has dramatically changed the clinical outcome in patients with acute coronary syndrome. At the same time as the beginning of thrombolysis, primary coronary angioplasty using balloon to the occluded culprit lesion showed highly successful reperfusion. After many clinical trials comparing primary angioplasty and thrombolysis, meta-analysis revealed that primary angioplasty improved the clinical outcome including death. 9) Furthermore, the introduction of stent decreased the ischemic events after intervention without mortality reduction ; however, the stent thrombosis with low incidence was a major problem. Several major clinical trials to prevent the stent thrombosis demonstrated that dual anti-platelet therapy (DAPT), the combination of aspirin and P2Y12 receptor antagonist, is the most effective agents to achieve the prevention of stent thrombosis. 10) In the recent survey in our country, 11) among patients with acute coronary syndrome almost 90% patients received stent and DAPT, and reflects the good clinical outcome. Therefore, anti-platelet agents have been recognized as the standard regime for the patients with coronary artery disease including acute coronary syndrome.
12) The real world registry, J-CAD, 13) showed the anti-platelet agent and statin improve the clinical outcome after adjusting several factors.
II. Anti-coagulants for the patients with acute coronary syndrome
Although the platelet adherence and aggregation following the plaque rupture is the initial step and formed the rigid platelet thrombus, thrombin is also produced at the culprit site. Tissue factors produced by the macrophage in the unstable plaque activate the coagulant cascade and produce thrombin, which also activate platelet aggregation and form the fibrin. The activation and coagulation cascade accelerate the thrombus formation at the culprit site and resulted in the narrowing or occlusion of the coronary vessels. In the acute phase, unfractionated heparin or low molecular heparin is widely used for patients with UA / NSTEMI 12) or fibrinolytic agents for patients with STEMI are also used routinely. Prothrombin fragment F1+2 is significantly increased in patients with acute coronary syndrome compared to the patients with stable coronary artery in the acute phase as well as 6 months after the onset. 14) This finding suggests that the coagulation cascade is activated continuously even in the chronic phase. Following this evidence, a number of clinical trials have assessed the safety and efficacy of oral anticoagulant agents administered to patients with acute coronary syndrome. In comparison with placebo, oral anticoagulants reduced the incidence of death, reinfarction, and stroke, compared to placebo and compared to aspirin. In WARIS II, 15) patients with acute coronary syndrome were randomized to warfarin, aspirin and both and with AF, apixaban and rivaroxaban were studied in patients after acute coronary syndrome for the secondary prevention. A randomized, double-blind, placebo-controlled clinical trial comparing apixaban, at a dose of 5 mg twice daily, with placebo, in addition to standard antiplatelet therapy, in high risk patients with a recent acute coronary syndrome for recurrent ischemic events was conducted(APPREASE II). 25) This trial was terminated prematurely after recruitment of 7,392 patients because of an increase in major bleeding events with apixaban in the absence of a counterbalancing reduction in recurrent ischemic events. Thus, the addition of apixaban, at a dose of 5 mg twice daily, to antiplatelet therapy in high-risk patients after an acute coronary syndrome increased the number of major bleeding events without a signifi cant reduction in recurrent ischemic events. Apixaban, at a dose of 5 mg twice daily, or placebo was administrated to patients with a recent acute coronary syndrome and at high risk and factors for recurrent ischemic events. The preventive effect of recurrent cardiovascular events of rivaroxaban was also tested in patients with recent acute coronary syndrome. 26) In this double-blind, placebo-controlled trial, patients with a recent acute (Fig. 1) . These results indicated the higher incidence in Asians but its preventive effect is weaker in Asians. On the other hand, there were no correlation between the incidence of intracranial hemorrhage and center TTR in both Asians and non-Asians, and the incidence of ICH is about 3 or 4 times higher than in nonAsians (Fig. 2) . These results demonstrated that ICH occurs in spite of the good control of warfarin, and the prospective study confirms the previous epidemic data ; the ICH incidence is 4 times higher than in Caucasian under warfarin control. 24) Figure   3 and 4 showed the incidence of stroke/systemic thromboembolism and ICH in NOAC of each studies, respectively. Although the both incidences are slightly higher in Asians than in nonAsians, but the difference is not remarkable compared to warfarin. The reason for the differences between NOAC and warfarin in terms of race is not clear. Genetic back ground or life style including food might explain the difference ; however, NOAC is more benefi cial in Asians rather than non-Asians.
IV. NOAC in acute coronary syndrome
Among the clinical trials for prevention of stroke in patients AF, the default is to step down to anticoagulation in monotherapy after 1 year, except for those with a very high risk for coronary events and an acceptably low bleeding risk.
34)
Secondary, should we use NOAC besides warfarin? As dis- Taking these risk and benefit consideration, we should evaluate the net clinical benefit in each patient and then select the appropriate combination so far.
VII. Conclusion
Warfarin is the only one oral anticoagulant for five decades. 
